+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| # BIOGRAPHICAL SKETCH           |   |       |        |                 |
|                                 |   |       |        |                 |
| Provide the following           |   |       |        |                 |
| information for the key         |   |       |        |                 |
| personnel and other significant |   |       |        |                 |
| contributors in the order       |   |       |        |                 |
| listed on Form Page 2.\         |   |       |        |                 |
| Follow this format for each     |   |       |        |                 |
| person. **DO NOT EXCEED FOUR    |   |       |        |                 |
| PAGES.**                        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| NAME                            |   | POS   |        |                 |
|                                 |   | ITION |        |                 |
| Gary S. Gilkeson                |   | TITLE |        |                 |
|                                 |   |       |        |                 |
|                                 |   | Staff |        |                 |
|                                 |   | Physi |        |                 |
|                                 |   | cian, |        |                 |
|                                 |   | Ralph |        |                 |
|                                 |   | H.    |        |                 |
|                                 |   | Jo    |        |                 |
|                                 |   | hnson |        |                 |
|                                 |   | VAMC  |        |                 |
|                                 |   |       |        |                 |
|                                 |   | Profe |        |                 |
|                                 |   | ssor, |        |                 |
|                                 |   | Me    |        |                 |
|                                 |   | dical |        |                 |
|                                 |   | Unive |        |                 |
|                                 |   | rsity |        |                 |
|                                 |   | of    |        |                 |
|                                 |   | South |        |                 |
|                                 |   | Car   |        |                 |
|                                 |   | olina |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| eRA COMMONS USER NAME           |   |       |        |                 |
|                                 |   |       |        |                 |
| gilkeson                        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| EDUCATION/TRAINING *(Begin with |   |       |        |                 |
| baccalaureate or other initial  |   |       |        |                 |
| professional education, such as |   |       |        |                 |
| nursing, and include            |   |       |        |                 |
| postdoctoral training.)*        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| INSTITUTION AND LOCATION        | D |       | Y      | FIELD OF STUDY  |
|                                 | E |       | EAR(s) |                 |
|                                 | G |       |        |                 |
|                                 | R |       |        |                 |
|                                 | E |       |        |                 |
|                                 | E |       |        |                 |
|                                 |   |       |        |                 |
|                                 | * |       |        |                 |
|                                 | ( |       |        |                 |
|                                 | i |       |        |                 |
|                                 | f |       |        |                 |
|                                 | a |       |        |                 |
|                                 | p |       |        |                 |
|                                 | p |       |        |                 |
|                                 | l |       |        |                 |
|                                 | i |       |        |                 |
|                                 | c |       |        |                 |
|                                 | a |       |        |                 |
|                                 | b |       |        |                 |
|                                 | l |       |        |                 |
|                                 | e |       |        |                 |
|                                 | ) |       |        |                 |
|                                 | * |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| Baylor University, Waco, TX     | B |       | 1975   | Biology         |
|                                 | S |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| Southwestern Medical School,    | M |       | 1979   | Medicine        |
| Dallas, TX                      | D |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+

**A. Positions and Honors**

1979-82, Intern/Resident, Medicine, North Carolina Memorial Hospital,
Chapel Hill, NC; 1982-86; Staff Internist, USAF Regional Hospital,
Carswell AFB, TX;1986-89 Fellow, Rheumatology, Duke University Medical
Center, Durham, NC; 1989-90 Associate in Medicine, Duke University
Medical Center; 1990-95 Assistant Professor of Medicine, Duke U. Medical
Center, 1992-96 Chief of Rheumatology, Durham VA Medical Center;1994-96
Assistant Professor of Immunology, Duke U. Medical Center;1995-96;
Associate Professor of Medicine, Duke U. Medical Center; 1996- Associate
Professor of Medicine/Microbiology and Immunology with tenure, Medical
University of South Carolina, Charleston, SC; 1996-present, Chief of
Rheumatology, Ralph H. Johnson VAMC. 2000-Professor of
Medicine/Microbiology and Immunology, MUSC; 2006-present, Vice-Chairman
for Research, MUSC Department of Medicine

**Honors**:1975-summa cum laude graduate, Baylor University; 1978- Alpha
Omega Alpha, UT Southwestern Medical School; 1989-Senior Rheumatology
Scholar Award, American College of Rheumatology; 1993-Henry Christian
Award for excellence in research, American Federation of Clinical
Research; 1994- American Association of Immunologist; 1992-95 Chairman,
Carolinas Chapter, Arthritis Foundation; 1993-1995 Chairman, Molecular
Biology Study Section, Arthritis Foundation; 1997-Southern Society of
Clinical Investigation; 1997-2001 NIH General Medicine A1 Study Section
member. 1998-2000 Associate Editor, Journal of Immunology. 1999-
Editorial Board, Clinical Immunology. 2000-2003, National Medical
Research Advisory Group for Immunology, Veteran\'s Administration. 2001-
National Volunteer Service Citation, Arthritis Foundation. 2003-SLE
Kirkland Scholar Award- Hospital for Special Surgery. 2007-MUSC
Foundation Outstanding Clinician Award. 2007- Autoimmunity Section
Editor, Clinical Immunology

**Committees**: National Arthritis Foundation- Board of Delegates,
1994-95, Medical and Scientific Committee, 1995-1997, Professional
Education Committee, 1997-01, Medical and Scientific Council, 2005.
American College of Rheumatology- Communications and Marketing
Committee; Chair- ACR Internet Subcommittee 1996-99. American College of
Rheumatology Lupus Study Group, 1998-01; Professional Education
Committee, 2000-03, Committee on Research, 2004-2006. Lupus Foundation
Medical and Scientific Board, 1999-04, Chairman, 2004-. Lupus Foundation
National Board of Directors, 2004-

**B. Selected peer-reviewed publications**: (from a total of 122)

**Gilkeson G,** Grudier J, Karounos D, Pisetsky D. Induction of anti-ds
DNA antibodies in normal mice by immunization with bacterial DNA. J.
Immunol. 142:1482-1486, 1989.

**Gilkeson G**, Bloom D, Pisetsky D, Clarke S. Molecular
characterization of anti-DNA antibodies induced in normal mice by
immunization with bacterial DNA. J. Immunol. 151:1353-1364, 1993.

Weinberg J, Granger D, Pisetsky D, Seldin M, Misukonis M, Wood E,
**Gilkeson G**. The role of nitric oxide in the pathogenesis of
spontaneous murine autoimmune disease. J. Exp. Med. 179:651-660, 1994.

**Gilkeson G**, Pippen A, Pisetsky D. Induction of crossreactive
anti-dsDNA antibodies in preautoimmune NZB/NZW mice by bacterial DNA
immunization. J. Clin. Invest. 95:1398-1402, 1995.

**Gilkeson G**, Ruiz P, Alexander A, Pippen A, Lefkowith J, Pisetsky D.
Modulation of renal disease in autoimmune NZB/NZW mice by immunization
with bacterial DNA. J. Exp. Med. 183:1389-1398, 1996.

Wloch M, Alexander A, Pippen A, Lefkowith J, Pisetsky D, **Gilkeson G**.
Differences in Vk gene utilization and VH CDR3 sequence among anti-DNA
from C3H-lpr mice and lupus mice with nephritis. Eur. J Immunol.
26:2225-2232, 1996

Lefkowith J, Di Valerio R, Norris J, Glick G, Alexander A, Jackson L,
**Gilkeson G**. Molecular characteristics of glomerulotropic
autoantibodies in murine lupus. J. Immunol. 157:1298-1305, 1996.

Lefkowith J, **Gilkeson G.** Nephritogenic autoantibodies in lupus:
Current concepts and continuing controversies. Arthritis Rheum.
39:894-903, 1996.

Wloch MK, Pippen AM, Alexander A, Lefkowith J, Pisetsky P, **Gilkeson
G**. Molecular characteristics of induced anti-DNA antibodies in
pre-autoimmune NZB/NZW mice. J. Immunol. 158: 4500-4506, 1997.

Oates, J, Alexander A, Ruiz P, Pippen A, **Gilkeson, G**. Effect of late
modulation of nitric oxide production on murine lupus. Clin. Immunol.
Immunopath. 83:86-92, 1997.

**Gilkeson G**, Mudgett J, Seldin M, Mishukonis M, Alexander A,
Weinberg. Serologic and clinical disease activity in MRL-lpr mice
lacking NOS2. J. Exp. Med. 186:365-373, 1997.

Carballo E, **Gilkeson G,** Blackshear P. Bone marrow transplantation
reproduces the tristetraprolin-deficiency syndrome in recombination
activating gene-2 (-/-) mice. J Clin. Invest 100:986-995, 1997.

Wloch M, Clarke S, **Gilkeson G**. Effect of VH CDR3 and light chain use
on binding of an anti-DNA antibody from a bacterial DNA immunized mouse.
J Immunol. 159:6083-6090, 1997.

Cooper G, Dooley MA, Treadwell E, St. Clair E, **Gilkeson G**.
Environmental and hormonal risk factors for the development of systemic
lupus erythematosus. Arthritis Rheum. 41:1714-1724, 1998.

Watanabe H, Sherris D, **Gilkeson G**. Effect of soluble CD16 on disease
in NZB/NZW mice. Clin Immunol Immunopath. 88:91-91, 1998.

**Gilkeson G**, Conover J, Pisetsky D, Feagin A, Halpern M, Klinman D.
Effect of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. J
Immunol. 161:3890-3895, 1998.

**Gilkeson G**, Cannon C, Oates J, Reilly C, Petri M. Correlation of a
serum measure of nitric oxide production with clincial disease activity
measures of lupus. J Rheum. 26:318-324, 1999.

Watanabe H, Circolo A, Holers M, Boackle S, Colten H, Wetsel R,
**Gilkeson G**. Modulation of renal disease in MRL/lpr mice deficient in
complement Factor B. J Immunol. 164:786-794, 2000.

Morel L, Croker B, Blenman K, Huang G, **Gilkeson G,** Wakeland E.
Genetic reconstitution of SLE immunopathology with poly-congenic B6.NZM
strains. Proc Natl Acad Sci. USA 97:6670-6675, 2000.

Reilly C, Oates J, Morrow J, Cook J, Halushka P, **Gilkeson G**.
Modulation of mesangial cell activation in MRL/lpr mice by prostaglandin
J~2~. J Immunol.164:1498-1504, 2000.

Molano I, Watanabe H, Wloch M, Alexander A, **Gilkeson G**. Effect of a
genetic deficiency of terminal deoxynucleotidyl transferase on
autoantibody production in Fas^lpr^ mice. Clin Immunol.94:24-32, 2000.

Sekine H, Reilly C, Molano I, Garnier G, Circolo A, Ruiz P, Holers VM,
Boackle SM **Gilkeson GS**. Complement Component C3 is Not Required for
Full Expression of Immune Complex Glomerulonephritis in MRL/*lpr*
Mice**.** J Immunol. 166:6444-6451, 2001.

Reilly C, Farrelly L, Viti D, Redmond S, Hutchison F, Ruiz P, Manning P,
Connor J, **Gilkeson G**. Modulation of renal disease in MRL/lpr mice by
pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int.
61:839-846, 2002.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, **Gilkeson GS**.
Hormonal and reproductive risk factors for development of systemic lupus
erythematosus: Results of a population-based, case-control study.
Arthritis Rheum. 46:1830-9, 2002.

Mishra N, Reilly CM, Brown DR, Ruiz P, **Gilkeson GS**. Histone
deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.
J Clin Invest. 111:539-552, 2003.

Thurman JM, Ljubanovic D, Edelstein CL, **Gilkeson GS**, Holers VM. Lack
of a functional alternative complement pathway ameliorates ischemic
acute renal failure in mice. J Immunol. 170:1517-1523, 2003.

Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, **Gilkeson GS**. Effects
of complement factor D deficiency on the renal disease of MRL/lpr mice.
Kidney Int. 65(1):129-138, 2004

Sekine H, Watanabe H, **Gilkeson GS**. Enrichment of anti-glomerular
antigen antibody-producing cells in the kidneys of MRL/MpJ-Faslpr mice.
J Immunol. 15;172(6):3913-21, 2004.

Zhang XK, Gallant S, Molano I, Moussa OM, Ruiz P, Spyropoulos DD, Watson
DK, **Gilkeson** G. Decreased expression of the Ets family transcription
factor Fli-1 markedly prolongs survival and significantly reduces renal
disease in MRL/lpr mice. J Immunol. 173(10):6481-9, 2004.

Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA,
**Gilkeson GS**. Modulation of renal disease in MRL/lpr mice by
suberoylanilide hydroxamic acid. J Immunol. 173(6):4171-8, 2004.

Thurman JT, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell
LM, Giclas PC, Salmon J, **Gilkeson G,** and Holers VM. ^.^A novel
inhibitor of the alternative complement pathway prevents
antiphospholipid antibody-induced pregnancy loss in mice. Molecular
Immunol. 2005;42:87-97.

Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, **Gilkeson GS**.
Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary
for synthetic PPARgamma agonist inhibition of inducible nitric-oxide
synthase and nitric oxide. J Pharmacol Exp Ther. 2005; 312:69-76.

Ginzler, E, Dooley, M, Aranow C., Kim M, Buyon J, Merrill J, Petri M,
**Gilkeson G**. Wallace M. Weisman M, Appel G. Comparison of
Mycophenolate Mofetil to Intravenous Cyclophosphamide for Induction
Therapy of Severe Active Lupus Nephritis. NEJM. 2005; 353(21):2219-28.

Reilly CM, Olgun S, Goodwin D, Gogal RM Jr, Santo A, Romesburg JW, Ansar
Ahmed S, **Gilkeson GS**. Interferon regulatory factor-1 gene deletion
decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol.
2006;36:1296-308.

Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, **Gilkeson GS**, Behrens
TW. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun.
2006;7:156-68.

Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, **Gilkeson GS**.
Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev.
2006;5:114-7.

Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ,
**Gilkeson GS**. Inflammatory modulation of PPAR gamma expression and
activity. Clin Immunol. 2006;118:276-83.

[Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, Utz PJ, **Gilkeson
GS**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17082662&query_hl=1&itool=pubmed_docsum)
Role of MHC-Linked Genes in Autoantigen Selection and Renal Disease in a
Murine Model of Systemic Lupus Erythematosus. J Immunol.
2006;177:7423-34

[Nowling TK, **Gilkeson
GS.**](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16890890&query_hl=1&itool=pubmed_docsum)
Regulation of Fli1 gene expression and lupus. Autoimmun Rev.
2006;5:377-82.

[Oates JC, **Gilkeson
GS**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16861040&query_hl=1&itool=pubmed_docsum)
The biology of nitric oxide and other reactive intermediates in systemic
lupus erythematosus..Clin Immunol. 2006;118:437-442.

[Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, **Gilkeson
GS**, Bottinger EP, Putterman
C.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16804897&query_hl=1&itool=pubmed_docsum)
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr
mouse glomerular mesangial cells.Arthritis Rheum. 2006;54:2198-210.

Miwa T, Maldonado MA, Zhou L, Yamada K, **Gilkeson GS,** Eisenberg RA,
Song WC. Decay-accelerating factor ameliorates systemic autoimmune
disease in MRL/lpr mice via both complement-dependent and -independent
mechanisms. Am J Pathol. 2007; 170(4):1258-66.

Sekine H, Ferreira RC, Pan-Hammarstrom Q, Graham RR, Ziemba B, de Vries
SS, Liu J, Hippen K, Koeuth T, Ortmann W, Iwahori A, Elliott MK, Offer
S, Skon C, Du L, Novitzke J, Lee AT, Zhao N, Tompkins JD, Altshuler D,
Gregersen PK, Cunningham-Rundles C, Harris RS, Her C, Nelson DL,
Hammarstrom L, **Gilkeson GS**, Behrens TW\*. Role for Msh5 in the
regulation of Ig class switch recombination. Proc Natl Acad Sci U S A.
2007;104(17):7193-8. \* Gilkeson and Behrens were co-senior authors on
this manuscript

Lenderink AM, Liegel K, Ljubanovic D, Coleman KE, **Gilkeson GS**,
Holers VM,Thurman JM. The alternative pathway of complement is activated
in the glomeruli and tubulointerstitium of mice with adriamycin
Nephropathy. Am J Physiol Renal Physiol. 2007;293(2):F555-64.

Alexander JJ, Jacob A, Vezina P, Sekine H, **Gilkeson GS**, Quigg RJ.
Absence of functional alternative complement pathway alleviates lupus
cerebritis. Eur J Immunol. 2007; 37(6):1691-701.

**Kamen DL**, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T,
James JA, Scofield RH, Harley JB, Gilkeson GS. Autoantibody Prevalence
and Lupus Disease Characteristics in a Unique African American
Population. Arthritis Rheum 2007, (in press).

**C. Research Support**

Role of Estrogen receptors in lupus

Principal Investigator: Gary S. Gilkeson, M.D.

Agency: Veterans Administration Type: Merit Review Period:
10/1/95-9/30/2009

The major goals of this project are to define the role of estrogen
receptors in lupus mice

Role of Sphingosine Kinase in Inflammatory Arthritis

Principal Investigator: Gary S. Gilkeson, M.D.

Agency: ACR-REF Type: Innovative Basic Research grant Period:
7/1/07-6/30/09

Goals are to test the hypothesis that SK1 derived S1P is a key component
of the inflammatory response in the rheumatoid joint and that targeting
this pathway is a novel approach in the treatment of rheumatoid
arthritis.

Role of nitric oxide in systemic lupus erythematosus

Principal Investigator: Gary S. Gilkeson, M.D.

Agency: NIAMS Type: NIH RO1 AR45476 Period 4/1/99-2/28/08

Aims to study the utility of nitric oxide (NO) as a marker of lupus
disease activity as well as its potential as a therapeutic target. Seeks
to define the tissue effects of NO in disease, the immune mediators that
lead to NO production, and if PBMC apoptosis is aberrant in human lupus
and the role NO plays in apoptosis in human lupus.

'

Multidisciplinary Clinical Research Center for Rheumatic Diseases in
African Americans

Principal Investigator: Richard Silver MD, Gary Gilkeson MD co-PI and PI
of Project 3

Agency: NIH Type: P60 AR049459 Period 4/15/03-3/31/08

The goal of this project is to determine the environmental and genetic
interactions resulting in poor renal outcome of African Americans with
lupus nephritis.

Targeted Complement inhibitors in lupus

Principal Investigator: Steve Tomlinson

Agency: DOD Type: US Army Period: 8/1/07-5/31/11

The goal of this research is to use targeted complement inhibitors for
treating lupus nephritis. This grant supports the development of
CR2-Crry and CR2-CD59 and integrin targeted therapies in MRL/lpr mice.
Gilkeson is Co-PI.

Vitamin D in Lupus

Principal Investigator: John Hardin

Agency: Alliance for Lupus Research Type: Foundation Period:
1/1/07-12/31/08

Multicenter treatment study with 2 specific aims: In the first, the
vitamin D precursor cholecalciferol will be administered to patients
with lupus to assess the safety and efficacy of the minimal dose
required to achieve full vitamin D replacement (serum 25D\>32ng/ml). In
the second, patients in whom vitamin D is fully replaced will be
compared with conventionally treated control patients (400IU/day) to
determine if this treatment modulates one or more components of the
vicious cycle of lupus pathogenesis. Gilkeson is Co-I.

Complement in the Pathogenesis of Autoimmune Arthritis

Principal Investigator: Michael Holers

Agency: NIH NIAMS AR051749-01 Period: 09/01/04-08/31/08

The major goals of this project are to determine the role of the
alternative pathway of complement in the development of joint
inflammation and injury in CIA. Gilkeson is PI of MUSC subcontract.

LCTC Participating Center

Principal Investigator: Gary Gilkeson

Agency: Lupus Clinical Trials Consortium, Inc Period: 1/1/04-12/31/06

MUSC is an LCTC site that participates in clinical trials for promising
new therapies for SLE. The LCTC provides support for a Clinical Director
and research nurse coordinator to perform clinical studies.

Training Grant in Inflammatory and Fibrosing Diseases

Principal Investigator: Gary Gilkeson

Agency: NIAMS Type: T32 AR050958 Period: 7/1/05-6/30/10

Grant to focus on defining societal, environmental and genetic factors
that impact morbidity and mortality in African Americans with rheumatic
diseases, specifically lupus and scleroderma

**Completed**

Role of PPAR in SLE

Principal Investigator: Gary Gilkeson, M.D.

Agency: NIAMS Type: NIH RO1 AR47451 Period 3/01/01-11/31/06

The study aims to assess the role of PPAR in SLE and the use of PPAR
agonists as treatment for SLE. This grant will not be renewed.

Role of complement factor B in the pathogenesis of SLE

Principal Investigator: Gary Gilkeson, M.D.

Agency: NIAID Type: NIH R01 AI47469 Period 4/1/00-3/31/06

Study aims to further define the role of Factor B in immune complex
mediated diseases and activation of C3.

Targeted complement inhibition in lupus nephritis

Principal Investigator: Steven Tomlinson

Agency: Alliance for Lupus Research Period: 1/01/04-12/30/06

The goal of this research is to use targeted complement inhibitors for
treating lupus nephritis